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Abstract. Repulsive guidance molecule (RGM) family mem-
bers RGMA, RGMB and RGMC are GPI-linked membrane 
proteins recently identified as co-receptor of bone morphoge-
netic proteins (BMPs). BMPs are a group of proteins enriched 
in bone and play important roles in prostate cancer. The 
current study aimed to investigate roles played by RGMs in 
prostate cancer. Expression of RGMs was examined in pros-
tate cancer cell lines and prostate cancer tissues using RT-PCR 
and immunohistochemical staining. Knockdown of each RGM 
in prostate cancer cells was performed using the respective 
anti-RGMA, RGMB and RGMC transgenes. A variety of in 
vitro function tests were employed to analyze the influence on 
cancer cell functions by RGM knockdown. The implications 
of RGM knockdown in BMP signalling were also examined 
using both Western blot and real-time quantitative PCR. 
Knockdown of RGMA had no effect on cell growth, migration 
and invasion, but promoted cell-matrix adhesion. Knockdown 
of RGMB and RGMC increased growth and adhesion, but 
only RGMB knockdown increased capacities of migration 
and invasion in PC-3 cells. Further investigations showed an 
increase in Smad-3 activation and reduced levels of Smad-1 
in PC-3 cells by RGMB and RGMC knockdown, and also an 
up-regulation of ID1, a BMP target gene particularly in expo-
sure to BMP7. RGMs play inhibitory roles in prostate cancer 
by suppressing cell growth, adhesion, migration and invasion. 
RGMs can coordinate Smad-dependent signalling of BMPs in 
prostate cancer cells.
Introduction
Bone morphogenetic proteins (BMPs) have been indicated in 
the disease progression of prostate cancer, particularly in the 
disease specific bone metastasis (1). A group of novel BMP 
co-receptors, namely repulsive guidance molecules (RGMs)-A, 
-B and -C were recently identified. RGMs are GPI-linked 
membrane proteins, sharing 50-60% sequence homology (2-4). 
RGMA mediates repulsive axonal guidance and neural tube 
closure, and RGMC is mutated in juvenile hemochromatosis. 
RGMB, also known as Dragon, is a myelin-derived inhibitor 
of axon growth in the central nerve system (5) and regulates 
the patterning of the developing nervous system (6). As BMP 
co-receptors, RGMA can increase binding of BMP ligands to 
ActRIIA, a type II receptor, and lead to an enhanced signal-
ling by BMP-2 and BMP-4 (7). RGMA enhances signalling of 
BMP-2 and BMP-4, leading to activation of Smad dependent 
pathway and up-regulation of a target gene, ID1 (2). RGMA is 
also crucial as a co-receptor for Hepcidin expression induced by 
BMP-2 and BMP-4, thus to maintain systemic iron homeostasis 
(8). RGMB directly interacts with BMP receptors, enhancing 
binding to their ligands, such as BMP-2 and BMP-4, but not 
BMP-7 (6). RGMB can negatively regulate IL-6 expression in 
immune cells through Smad-independent signalling by BMPs, 
including p38 and ERK pathways (9). On the other hand, upon 
binding to its ligand neogenin, RGMA may also mediate growth 
cone collapse in neurites which has been shown as indepen-
dent from BMPs signalling (10). A recent study also revealed 
that secreted von Willbrand factor type D domain of RGMB 
suppressed Smad-dependent signal transduction by BMPs, 
in which unknown receptors were involved (11). Similarly, 
upon binding to its receptor neogenin, RGMC is stablized by 
anchoring on the cell membrane, which could compromise its 
inhibition on BMP signalling (12).
BMPs play profound roles in prostate cancer and the disease 
specific bone metastasis by regulating proliferation, apoptosis 
and motility of prostate cancer cells, and also tumour associ-
ated angiogenesis. For example, BMP-7 and BMP-9 inhibit the 
proliferation of PC-3 prostate cancer cells via inducing apoptosis 
through BMP receptors and Smad-dependent pathway (13,14), 
while BMP-10 inhibits the growth of prostate cancer cells via 
Smad-independent signalling in which XIAP and ERK1/2 are 
involved (15). Therefore as BMP co-receptors, RGMs might 
also be involved in the prostate cancer development and metas-
tasis through the participation in BMP signalling pathway. To 
date, there is only one study investigated the implication of 
RGMs in cancer, in which an epigenetic down-regulation of 
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RGMA was revealed in colorectal carcinomas, adenomas and 
colorectal cancer cell lines (16). However, the role played by 
RGMs in prostate cancer remains unknown. The present study 
aimed to examine the expression of RGMs in prostate cancer 
and their functions in prostate cancer cells.
Materials and methods
Materials. Antibodies to RGMA, RGMB, RGMC, phos-
phorylated Smad-1, and Smad-3 were obtained from Santa 
Cruz Biotechnology, CA. Human recombinant protein BMP-7 
(rh-BMP7) was purchased from R&D System, Inc. (Abingdon, 
UK). All the primers were synthesized by Invitrogen (Paisley, 
UK), as shown in Table I.
PC-3 cell line was purchased from European Collection 
of Animal Cell Culture, Salisbury, UK; DU-145, LNCaP, 
CA-HPV-10 and PZ-HPV-7 from American Type Culture 
Collection. PNT-1A and PNT-2C2 were kindly provided by 
Professor Norman Maitland (University of York, UK). The 
cells were routinely maintained in DMEM supplemented with 
10% fetal calf serum and antibiotics.
Prostate tissue samples were snap-frozen in liquid nitrogen 
immediately after radical prostatectomy, transurethral prosta-
tectomy or prostate biopsy. All protocols were reviewed and 
approved by the local ethics committee and all patients gave 
written informed consent.
Immunohistochemical (IHC) staining procedure for frozen 
prostate tissue. Frozen specimens of prostate tumours (n=8) 
and normal prostate tissues (n=13) were cut at a thickness 
of 6 µm using a cryostat, and verified by two pathologists. 
IHC was performed using respective primary antibody and 
Vectastain Universal Elite ABC kit (Vector Laboratories, 
Peterborough, UK). The density of the IHC staining was quan-
tified using ImageJ (http://rsbweb.nih.gov/).
Generation of RGM ribozyme transgenes. Specific hammer 
head ribozymes targeting human RGMA, RGMB and RGMC 
were designed and synthesised following previously described 
procedure (17). The ribozymes were cloned into pEF6/His 
TOPO mammalian expression plasmid vectors (Invitrogen Inc., 
Paisley, UK). Control empty plasmid vectors and the ribozyme 
transgenes were then transfected into PC-3 cells, followed by 
two weeks of selection using 5 µg/ml blasticidin. Knockdown 
of specific RGM was then confirmed before further use.
RNA isolation, reverse transcription and polymerase chain 
reaction (PCR). RNA isolation was carried out using TRI 
reagent from Sigma. RNA (0.5 µg) was converted into cDNA 
using the iScript™ cDNA Synthesis kit (Bio-Rad, Hemel 
Hemstead, UK). 
Real-time quantitative PCR. The real-time quantitative PCR 
was carried out to determine the levels of RGM transcripts and 
ID1 in the control and RGM knockdown cells. The assay was 
based on the Amplifuor technology and primers were designed 
using Beacon Designer software which included complemen-
tary sequence to universal Z probe (Intergen Inc., Oxford, UK), 
as previously reported (18,19). The primers used for RGMs 
and ID1 quantification and housekeeping GAPDH are listed in 
Table I.
Protein extraction, SDS-PAGE and Western blot analysis. 
Following cell lysis, the protein concentration was quantified 
using the DC Protein Assay kit (Bio-Rad, USA) and a spec-
trophotometer (Bio-Tek, ELx800). Equal amounts of protein 
from each sample were loaded onto 8% polyacrylamide gel and 
following SDS-PAGE, the proteins were transferred onto nitro-
cellulose membranes subjected to blocking, and probing with 
the specific primary (1:200), and the corresponding peroxidise-
conjugated secondary antibodies (1:2000). The protein bands 
were eventually visualized using the Supersignal™ West Dura 
system (Pierce Biotechnology, USA).
In vitro cell growth assay. The cells were seeded into a 96-well 
plate at a concentration of 3,000 cells per well, and incubated for 
periods of up to 5 days. The cells were then stained with crystal 
violet, and measured the absorbance. The results are shown as 
growth rate which was calculated by normalization against the 
absorbance measurements at day 0.
In vitro cell-matrix adhesion assay. 45,000 cells were seeded 
onto the 96-well plate coated with Matrigel basement membrane 
in 200 µl of normal medium and incubated for 40 min. After 
washing, adherent cells were fixed and visualized under the 
microscope under x40 objective magnification and random 
fields counted.
In vitro cell invasion assay. Transwell inserts (upper chamber) 
with an 8 µm pore size were coated with 50 µg/insert of Matrigel 
and air-dried, before being rehydrated with normal medium. 
Then, 2x104 cells were added to each well. After 72 h, cells 
that had migrated to the other side of the insert through the 
matrix were fixed and stained with 0.5% (w/v) crystal violet. 
The invaded cells stained with crystal violet were counted under 
a microscope.
In vitro cell motility assay using cytodex-2 beads. Cellular 
motility was assessed using a cytodex-2 bead motility assay. 
Cells (5x105) for each cell type were incubated in 10 ml of growth 
medium containing 100 µl of cytodex-2 microcarrier beads (GE 
Healthcare, Cardiff, UK) for 3.5 h to allow the cells to adhere 
to the beads. After washing the beads were resuspended in 
growth medium, seeded into a 24-well plate and then incubated 
overnight at 37˚C. Cells that had migrated from the beads and 
adhered to the base of the well were fixed in 4% formaldehyde 
(v/v), stained with 0.5% crystal violet (w/v) and counted under 
x40 objective magnification.
ECIS-based attachment and migration assay. We used the 
electric cell-substrate impedance sensing (ECIS) system 
(Applied Biophysics, Inc., Troy, NY) to conduct the attachment 
and wounding assay). PC-3 cells were cultured in 8W1E ECIS 
arrays (Applied Biophysics). We seeded PC-3 cells at a density 
of 70,000 cells/well in the arrays. The cells were incubated for 
4 h and the resistance was recorded every 15 sec. Once the 
cells fully attached, the monolayer was electrically wounded by 
applying an elevated voltage pulse with a frequency of 30 kHz, 
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amplitude of 4 V for 10 sec. Cell migration was assessed by 
continuous resistance measurements for 30 h.
Statistical analysis. Normally distributed data were analyzed 
using the two sample t-test while non-normally distributed data 
were analyzed using the Mann-Whitney and Kruskal-Wallis 
tests.
Results
Expression of RGMs in prostate cancer. The expression of 
RGMs was examined in prostate cancer cell lines and prostate 
cancer tissues using RT-PCR. RGMs were expressed in most 
of the prostate cancer cell lines. No remarked difference was 
seen in RGM expression between prostate cancer cells and 
the immortalised prostatic epithelial cells. RGMB was not 
expressed in CAHPV-10 cells, and RGMC was barely detect-
able in LNCaP cells. Among the RGMs, RGMA mRNA was 
hardly detectable in the two prostate cancer tissues examined 
(Fig. 1).
To further investigate the expression of RGMs in prostate 
tissues, we examined their protein levels using immunohisto-
chemical staining. RGM protein was mainly confined to the 
cytoplasm of cancer cells and some of the mesenchymal cells 
on the periphery of the tumour area. The immunochemical 
staining of RGMB and RGMC protein revealed subtle stronger 
staining in prostate cancer cells compared to prostate epithelial 
cells, while staining of RGMA is much weaker in both prostatic 
epithelia and cancer cells (Fig. 2A). The intensity of the staining 
in the cells was measured and calculated based on the back-
ground using ImageJ. The quantification of the IHC staining 
shows the levels of RGMB and RGMC in prostate tumours were 
significantly higher, compared to background tissues (P<0.05) 
(Fig. 2D).
Knockdown of RGMA, RGMB and RGMC in PC-3 cells. To test 
the potential role of RGMs in prostate cancer cells, knockdown 
of RGMA, RGMB and RGMC in PC-3 cells were performed 
using the respective anti-RGM transgenes. The knockdown of 
RGMs mRNA and protein were then verified using both real-
time quantitative PCR and Western blotting (Fig. 3).
Effect on in vitro growth of prostate cancer cells by RGMs knock-
down. Following the verification of knockdown, we examined 
effect on functions of prostate cancer cell by RGMs knockdown. 
Firstly, we assessed the influence on cell growth. Compared to 
control cells, PC-3ΔRGMA cells did not show difference in cell 
growth (p=0.07). In contrast, PC-3ΔRGMB and PC-3ΔRGMC cells 
showed increase in cell growth, both p<0.05 compared to PC-3pEF 
control cells (Fig. 4A).
Influence on cell-matrix adhesion by knockdown of RGMs in 
prostate cancer cells. In the adhesion assay, reduced expression 
of RGMs (RGMA, B and C) in PC-3 cells increased cell adhe-
sion, compared to the control cells. The number of cells adhered 
to matrix for PC-3ΔRGMA (26.93±13.23), PC-3ΔRGMB (30.67±12.43), 
PC-3ΔRGMC (30±12.43) were increased, p<0.05 compared to 
PC-3pEF control cells (16.67±8.09) (Fig. 4B).
Effect on motility and invasiveness of prostate cancer cells 
by RGMs knockdown. Furthermore, RGM knockdown cells 
Figure 1. RT-PCR shows expression pattern of RGMs in prostate cancer cell 
lines. RGMs were expressed in most the prostate cancer cell lines and the 
immortalized prostatic epithelial cell lines. In the two prostate cancer tissue 
samples examined in current study, RMGB was expressed at relatively higher 
levels.
Table I. Primers used in this study.
Gene Sense (5'-3') Anti-sense (5'-3')
RGMA TCGACAATAATTACCTGAACG ACTGAACCTGACCGTACACCTGGAAGTTCTTGAAGATG
RGMB TTCAGGTTCAAGTGACAAACG ACTGAACCTGACCGTACATCATCTGTCACAGCTTGGTA
RGMC AATGACTTCCTCTTTGTCCA ACTGAACCTGACCGTACACATTCCTGCATGTTCTTAAA
RGMA CTGCAGGCGCACCACGATGGTGGTGCCC ACTAGTGGAGATCCAGGCCAAGTACATTTCGT
ribozyme TGATGAGTCCGTGAGGA CCTCACGGACT
RGMB CTGCAGGTCATCTGTCACAGCTTGGTA ACTAGTGTACAGATCAGAAAGTTTCGTCCTCACGGACT
ribozyme CTGATGAGTCCGTGAGGA
RGMC CTGCAGATCCCCCAGGTCGGTCACCTCC ACTAGTCCTGTAGCCTTTGAAGATGGTTCTATTTCGTC
ribozyme ATTCTGATGAGTCCGTGAGGA CTCACGGACT
ID1 TCAACGGCGAGATCAG ACTGAACCTGACCGTACAGATCGTCCGCAGGAA
GAPDH AAGGTCATCCATGACAACTT ACTGAACCTGACCGTACAGCCATCCACAGTCTTCTG
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Figure 3. Knockdown of RGMs in PC-3 cells. (A) Reduced protein expression of RGMs was verified in PC-3ΔRGMA, PC-3ΔRGMB and PC-3ΔRGMC cells, in comparison 
with PC-3pEF cells using Western blotting. (B) Real-time quantitative PCR revealed reduced transcript level of RGMs by ribozyme transgenes. A significant reduction 
of RGMA transcripts was seen in PC-3ΔRGMA cells (1.05x105±1.20x104), p=0.007 compared with PC-3pEF control cells (5.76x106±1.05x106). Although reduced levels 
of RGMB and RGMC transcripts were seen in the corresponding cells, but there was no significant difference according the statistical results. *P<0.05 vs control.
Figure 2. IHC staining of RGMs in human prostate cancer. (A-C)  Immunochemical staining of RGMA, RGMB and RGMC in prostate cancer specimens, reduced 
from x40 and x400, respectively. (D) There is no significant difference of the staining of RGMA, RGMB and RGMC seen in the prostate cancer tissues when 
compared with background tissues using semi-quantification of the staining using ImageJ software. For negative control only secondary antibody was applied 
during the probing procedure. *P<0.05 vs normal prostate tissue.
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displayed increased motility, (Fig. 4C). The number of migrated 
PC-3ΔRGMA cells was 36±9.2, being 46.4±7.06 and 45.54±28.46 
for PC-3ΔRGMB and PC-3ΔRGMC cells, respectively. However, only 
the increase in PC-3ΔRGMB cells was statistically significant 
(p<0.01) compared with PC-3pEF control cells (20.2±4.06).
To further confirm the effect on cell motility by RGMs 
knockdown, we examined the cell migration using ECIS. The 
migration rate was much higher of PC-3∆RGMB cells compared 
to control, while the RGMA and RGMC knockdown has no 
significant effect on the migration (Fig. 5A). One hour after 
the wounding, the average impedance in PC-3ΔRGMB cells 
was significantly higher than the pEF control cells (p=0.009). 
However, the RGMA and RGMC knockdown cells did not show 
such significant effect on migration in the ECIS wounding assay 
(Fig. 5B). This is thus consistent with the observations using 
the afore-mentioned motility assay. We further demonstrated 
that knockdown of RGMs had no effect on invasion of prostate 
cancer cells (Fig. 4D).
Potential roles of RGMs in BMP Smad-dependent signalling 
and regulation of ID1 expression. To investigate effect on BMP 
signalling by RGMs knockdown in PC-3 cells, we analyzed 
levels of phosphorylated Smad-1 and Smad-3 in the cells, and 
also transcript levels of ID1. RGMs knockdown affected BMP 
signalling in PC-3 cells, the BMP downstream signalling mole-
cules (Smads) activation profile was examined, which might be 
associated with ID1 expression in these transfected cells.
RGMB and RGMC knockdown in PC-3 cells significantly 
increased Smad-3 activation, but not in PC-3ΔRGMA cells, 
compared to the control cells (Fig. 6A and B). The increased 
activation was enhanced by stimulation of rh-BMP7 (40 ng/ml, 
30 min), which indicated RGMB and RGMC knockdown can 
enhance the Smad-3 dependent pathway activated by BMP7 
(Fig. 6A and B). In contrast to the effect on Smad-3 phosphoryla-
tion, reduced levels of activated Smad-1 were seen in PC-3ΔRGMB 
and PC-3ΔRGMC cells, but not in PC-3ΔRGMA cells (Fig. 6A).
Figure 4. Effects on in vitro functions of PC-3 cells by RGMs knockdown. (A) Shown is the absorbance of day 3 which represented the cells number of each cell 
lines. The reduction of RGMB and C in PC-3 significantly promoted growth rate. (B) Knockdown of RGMs promoted cell-matrix adhesion of prostate cancer cells. 
(C) Knockdown of RGMB and RGMC resulted in elevated motility in PC-3 cells. (D) The invasiveness of PC-3 cells had not been altered by knockdown of RGMs. 
Minimum three independent experiments were conducted and a representative example is shown. *P<0.05 vs PC-3pEF/His.
Figure 5. Effect on cell migration by knockdown of RGMs was also deter-
mined using the ECIS assay. (A) PC-3∆RGMB cells showed marked increase in 
migration after wounding. (B) The mean of increased impedance (ohms) at 1 h 
after wounding was calculated based on three individual experiments. Error 
bars presents standard error. *P<0.05 vs PC-3pEF/His.
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Expression of ID1, a BMP responsive gene in these cells 
was then determined using real-time quantitative PCR. In line 
with the observation of activated Smad-3 in PC-3ΔRGMB and 
PC-3ΔRGMC cells, increased transcript levels of ID1 were evident 
in these cells and also in the cells exposed to BMP-7. Similarly, 
the up-regulation of ID1 was not seen in the PC-3ΔRGMA cells 
(Fig. 6C and D).
Discussion
In the present study, roles played by RGMs in prostate cancer 
were investigated. The expression of RGMA, RGMB and RGMC 
was evident in most examined prostate cancer cell lines, and 
also in the prostate cancer tissues. Although stronger staining 
of RGMB and RGMC was seen in prostate cancer cells in 
comparison to prostatic epithelia of normal prostate tissues, the 
association with disease development and progression requires 
further investigation in a large cohort and an animal model.
Knockdown of RGMs using hammerhead ribozyme trans-
genes resulted in accelerated cell growth and enhanced adhesion 
in vitro. Interestingly, the effects on cellular behaviour were 
most significant in RGMB knockdown cells. The knockdown of 
RGMB significantly enhanced the prostate cancer cell capacity, 
namely increased growth, adhesive, motility and mobility. 
RGMC knockdown did not affect cell motility, however, had an 
effect on cell growth and adhesion. In comparison to RGMB 
and RGMC, knockdown of RGMA only affected cell-matrix 
adhesion, but not growth, migration and invasion. It suggests 
that RGMs, particularly RGMB and RGMC trigger or mediate 
inhibitory effect on growth, adhesion and motility of prostate 
cancer cells.
To reveal what mechanism(s) is involved in the regulation 
of prostate cancer cells by RGMs, we investigated the effect of 
RGM  knockdown on Smad-dependent signal transduction. An 
increased activation of Smad-3 was evident in the PC-3 cells by 
knockdown of RGMB and RGMC, while activation of Smad-1 
was suppressed in these cells. It suggests RGMs, particularly 
RGMB and RGMC coordinate signal transduction of BMPs and 
divert the signal to be relayed via a different Smad.
DNA-binding protein inhibitor (ID1) proteins belong to the 
helix-loop-helix (HLH) transcriptional regulator family, and 
functions as an antagonists of basic HLH transcription factors 
by inhibiting their ability to bind specific DNA sequences 
within target gene promoters, thereby negatively regulate cell 
differentiation (20). Additionally, they have also been revealed 
to participate in tumour cell growth and promote cell survival 
in prostate cancer (21). ID1 is a direct downstream target gene 
of BMPs being induced by the BMP Smad-dependent signal-
ling pathway (22,23), promoting cell growth and inhibiting cell 
differentiation in breast cancer and prostate cancer (24,25). In 
the current study, up-regulation of ID1 expression was seen in 
PC-3 cells by knockdown of RGMB and RGMC, which were 
enhanced by addition of BMP7. The increased level of ID1 in 
RGM knockdown cells could at least partially be responsible 
Figure 6. Influence on Smad dependent signal transduction by RGM knockdown. (A) Activated Smad-3 expression was up-regulated after RGMB and RGMC were 
knocked down and this is enhanced by stimulation of BMP7 (40 ng/ml, 30 mins), while there is no significant change in phosphorylated Smad-1 levels. (B) Shown 
is the band volume of P-Smad-3 being normalized against corresponding GAPDH band volume. (C) ID1 transcript levels in the transfected cells were determined 
using real-time quantitative PCR. ID1 transcripts in RGMA, RGMB and RGMC knockdown cells were upregulated, being 4.93x107±2.83x107, 4.4x108±3.24x108 
and 6.49x108±3.77x108 respectively), p=0.52, 0.09 and 0.05 compared to PC-3pEF control cells (3.76x107±0.28x107). (D) The ID1 level was elevated in RGM 
knockdown cells in exposure to BMP7 treatment (40 ng/ml, 30 min) and this effect was strong in RGMB and RGMC. Shown is the copy numbers of each RGM 
normalised against corresponding GAPDH.
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for their effects (promotion) on cell proliferation, adhesion 
and motility. However, the regulation of ID1 expression may 
be mediated via Smad-3-dependent pathway, rather than the 
Smad-1 pathway as previously reported (26-29). Collectively, it 
was indicated that RGMB and RGMC exert their regulation both 
on endogenous and exogenous BMPs. Interestingly, the three 
RGM family members in prostate cancer seem not functionally 
complementary and associated, as after knockdown of each one 
the effect will not be substituted by the other two.
In conclusion, RGMs play inhibitory roles in prostate 
cancer by suppressing cell growth, adhesion, migration and 
invasion. RGMs can coordinate Smad-dependent signalling 
by BMPs in prostate cancer cells. The current study indicates 
the interesting role of RGMs in prostate cancer and a potential 
therapy target in the future.
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